KOSDAQBiotech & Pharma007390

Naturecell

₩24,850▼ 1.00%2026-10-02 close

Market Cap

₩1.6T

Turnover

₩4.7B

Volume

190,000 shares

Shares out.

64.4M

PER

—

PBR

24.5×

EPS

-₩42

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Between a US Filing Path and a Loss-Making Base

NatureCell sits between an event axis of JointStem's US filing process and a Nasdaq listing push, and an earnings axis of roughly KRW 20bn annual revenue with continuing operating losses.

1
The core pipeline JointStem, an autologous adipose-derived stem cell therapy, holds both RMAT and Breakthrough Therapy designations in the US, and a Breakthrough Therapy meeting with the FDA was held on May 21, 2026.
2
The company said it will hold a pre-BLA meeting with the FDA in the second half of 2026 before pursuing a filing, and the shareholder representative cited a November BLA submission target; no approval has been granted.
3
Domestically, the plaintiff won the first-instance suit to cancel the license rejection on July 9, 2026, but the MFDS appealed on July 30, moving the dispute to the appellate court.
4
Earnings turned positive in 2024 with revenue of KRW 32.3bn and operating profit of KRW 0.6bn, but reverted in 2025 to revenue of KRW 20.7bn and an operating loss of KRW 3.6bn, with quarterly operating losses continuing in the first half of 2026.
5
The debt-to-equity ratio was a low 18.6% at end-2025, yet the US GMP campus investment and the Nasdaq ADR listing push are tied to large-scale funding plans.

Business structure

NatureCell was founded in 1971, listed on KOSDAQ in 1992, adopted its current name in 2013, and in 2022 acquired 100% of Nature America in the US as a subsidiary.

Its operations span R&D and overseas trials of autologous adipose-derived stem cell therapies for rare and intractable diseases, stem-cell culture-medium cosmetics, and manufacturing and sales of vegan beverages.

The stem cell division is pursuing commercialization of an osteoarthritis therapy and overseas trials and also sells into the premium skincare market, though the profit contribution of that business is still described as weak.

The practical revenue base is consumer-facing cosmetics and beverages, while the therapeutic pipeline still shows up in the financials as cost and event risk rather than sales.

The core pipeline, JointStem, targets severe knee osteoarthritis by injecting stem cells derived from the patient's own adipose tissue into the joint cavity, and the domestic license applicant is affiliate R&L Regenerative Medicine Institute, formerly Albio.

NatureCell holds the domestic sales rights for JointStem and pursues the stem cell therapy business together with Albio, so the separation between the license applicant and the sales rights holder is the starting point for understanding the structure.

Beyond JointStem, the pipeline includes AstroStem for Alzheimer's disease, VascoStem for critical limb ischemia and AstroStem-AU for autism.

As a new revenue business the company has proposed amniotic stem cell banking from the placenta, targeting more than 4,000 domestic banking customers in 2026, and it said it has gathered prosumers through briefings for Korean-American communities in major US cities to push cosmetics into the US market from September 2026.

Competition runs both against other domestic cell therapy developers and, in knee osteoarthritis, against incumbent options such as hyaluronic acid and steroid injections and joint replacement surgery.

Earnings trend

Quarterly revenue · Operating profit

₩6.4B-₩300M25Q2₩3.9B-₩1.4B25Q3₩6.4B-₩300M25Q4₩4.1B-₩1.3B26Q1₩6.2B-₩700M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩21.6B-₩9.5B2022₩19.4B-₩10.3B2023₩32.3B₩600M2024₩20.7B-₩3.6B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩6.4B	-₩300M	−4.5%
2025Q3	₩3.9B	-₩1.4B	−35.7%
2025Q4	₩6.4B	-₩300M	−4.1%
2026Q1	₩4.1B	-₩1.3B	−32.6%
2026Q2	₩6.2B	-₩700M	−11.3%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩21.6B	-₩9.5B	-₩6.8B	−44.1%	−11.9%	64.5%
2023	₩19.4B	-₩10.3B	-₩11.7B	−53.1%	−19.0%	11.4%
2024	₩32.3B	₩600M	₩1.2B	1.8%	1.9%	11.4%
2025	₩20.7B	-₩3.6B	-₩2.8B	−17.6%	−4.5%	18.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

The annual pattern is highly volatile.

Revenue was KRW 21.5bn with a KRW 9.5bn operating loss in 2022 and KRW 19.3bn with a KRW 10.2bn operating loss in 2023, pushing operating margins to minus 44.1% and minus 53.1%, before 2024 turned positive with revenue of KRW 32.3bn, operating profit of KRW 0.6bn and net profit of KRW 1.2bn.

In 2025, however, revenue fell back to KRW 20.7bn with an operating loss of KRW 3.6bn and a net loss of KRW 2.8bn, returning the operating margin to minus 17.6%.

Because the revenue decline was larger in scale than the swing in operating loss, the 2024 profit is best read as a thin surplus that held only while revenue sat above the KRW 30bn line. Quarterly data show sharp swings.

Revenue fell from KRW 6.4bn in 2Q25 (operating loss KRW 0.29bn) to KRW 3.9bn in 3Q25 (operating loss KRW 1.39bn), recovered to KRW 6.35bn in 4Q25 (operating loss KRW 0.26bn, net profit KRW 0.34bn), then slid again to KRW 4.06bn in 1Q26 (operating loss KRW 1.32bn).

The latest confirmed quarter, 2Q26, showed revenue of KRW 6.20bn, an operating loss of KRW 0.70bn and a net loss of KRW 0.64bn, meaning revenue slipped slightly year on year while the operating loss widened.

Summing the four most recent quarters, from 3Q25 through 2Q26, revenue is around KRW 20.5bn with an operating loss in the KRW 3.6bn range and an owners' net loss of KRW 2.71bn, a profit structure similar to full-year 2025.

On the balance sheet, end-2025 equity was KRW 63.0bn against total liabilities of KRW 11.7bn for a debt-to-equity ratio of 18.6%, and operating cash flow improved from minus KRW 14.9bn in 2022 to plus KRW 1.5bn in 2024 and plus KRW 0.16bn in 2025.

That near-breakeven operating cash flow in 2025 also shows that US production investment and regulatory costs are of a scale that internally generated cash cannot cover.

Industry analysis

Knee osteoarthritis has a wide treatment gap between symptom-focused drugs and end-stage joint replacement surgery, and cell therapy developers are trying to enter on the basis of that unmet need.

JointStem is positioned around the possibility of affecting disease progression itself rather than only relieving pain, with structural improvement presented as the differentiator versus symptom-focused incumbents.

According to company descriptions, four trials reported roughly 45-56% pain reduction and about 39-55% functional improvement at six months, with durability observed after a single administration. The regulatory environment diverges by country.

Korea's MFDS rejected the product license, questioning whether the observed effect was meaningful enough for actual patients, while the US FDA assessed the potential to support further development and granted RMAT and Breakthrough Therapy designations.

That gap in regulatory judgment is itself a marker of where the advanced biopharmaceutical industry stands, and it has broadened into a debate over domestic review standards.

Another industry gate is manufacturing capability, since for cell therapies the ability to supply cells of consistent quality at commercial scale is a key evaluation factor.

In other words, even as filing milestones progress, CMC, process consistency and long-term safety data are reviewed together, making individual company readiness rather than an industry cycle the decisive variable.

Outlook

The US roadmap disclosed by the company is concentrated in 2026.

At a March 2026 investor briefing it presented a dual path combining accelerated approval and a conventional Phase 3, saying a May FDA meeting would finalize the strategy; it submitted a briefing package on April 21 and held the Breakthrough Therapy meeting on May 21.

At an investor reception during BIO USA 2026 in June, President Jung Sang-mok outlined JointStem's BLA preparations and said the company plans to hold a pre-BLA meeting with the FDA in the second half of the year before pursuing the filing.

The shareholder representative, citing the minutes of the May 21 meeting, said the plan is to request a BLA meeting by late July and submit the BLA by November, and stated the FDA indicated the filing could be prepared on completed Korean Phase 3 data without an additional US Phase 3; these are company and shareholder-side accounts, and any approval depends on future FDA review.

On the capital markets side, the company is pursuing a Nasdaq listing via a level 3 ADR structure, targeting an application between September and November 2026 and completion in the first half of 2027, and said discussions with investment banks are under way.

On capacity, it described a USD 300m five-year investment in a BIOSTAR Stemcell Campus in Baltimore, Maryland, targeting 20,000 doses a year upon completion in October 2026, 50,000 doses by the first half of 2027 and one million doses a year by 2031.

Timelines have been revised repeatedly, however: the Phase 3 application originally slated for February 2026 was pushed back until after the FDA meeting, and shareholder pushback over such changes has been reported.

Domestically, the appellate ruling and the MFDS's subsequent administrative steps remain the variables that will set any commercialization timing.

Valuation

PER

—

PBR

24.5×

ROE

-4.3%

EPS

-₩42

BPS

₩977

Dividend per share

₩0

Profit-based multiples do not compute. Over the four most recent quarters the owners' net result was a loss, so earnings-based multiples cannot be derived, and no dividend is paid, so dividend metrics offer no basis for comparison.

That leaves the multiple against net assets, and the company's price-to-book ratio sits far above the average for domestic biotech and pharma names and above the KOSDAQ average, meaning it trades at a very large premium to accounting net assets.

With annual revenue still in the KRW 20bn range, that gap implies the market value reflects future scenarios such as JointStem's US filing process, the Nasdaq listing and the US production campus, rather than current profits.

As a result, valuation is likely to track the progress of regulatory and listing milestones more than earnings metrics, and each schedule revision forces a recalculation of the expectations embedded in the price.

For reference, the company has stated a goal of achieving a corporate value above USD 10bn through the Nasdaq listing, which is a company target and should be distinguished from market assessment.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

US expedited designations and a more concrete BLA path

JointStem holds both RMAT and Breakthrough Therapy designations from the FDA and is using expedited development and review programs.

A Breakthrough Therapy meeting was held on May 21, 2026, and the shareholder representative, citing the minutes, said the FDA indicated a BLA could be prepared on Korean Phase 3 data without an additional US Phase 3.

At a June investor reception in the US the company also said it would pursue the filing after a pre-BLA meeting in the second half. A path that shortens development time and cost is a core premise in valuing the pipeline.

First-instance win reopens domestic review

On July 9, 2026 the Seoul Administrative Court ruled in favor of the plaintiff in the suit brought by R&L Regenerative Medicine Institute against the MFDS to cancel the license rejection.

The court held that under the Pharmaceutical Affairs Act the licensing requirements are safety and efficacy, with no legal basis for demanding superiority over existing therapies, and it also flagged fairness problems in the review procedure.

NatureCell holds the domestic sales rights to JointStem, so domestic approval would change its revenue structure materially. Industry observers stress, however, that winning the administrative suit and obtaining the product license are separate processes.

Low debt burden and a consumer revenue base

At end-2025 total liabilities were KRW 11.7bn against equity of KRW 63.0bn, a debt-to-equity ratio of 18.6%. That is far below the 64.5% ratio of 2022, and operating cash flow swung from minus KRW 14.9bn in 2022 to slightly positive in 2024 and 2025.

The presence of consumer revenue from cosmetics and beverages gives it a revenue base uncommon among development-stage biotech firms. That directly affects staying power when trial and regulatory timelines slip.

Bear factors

Shrinking revenue and a return to losses

In 2024 the company posted revenue of KRW 32.3bn and operating profit of KRW 0.6bn, but 2025 revenue fell to KRW 20.7bn with an operating loss of KRW 3.6bn.

In 1Q26 revenue was KRW 4.06bn with an operating loss of KRW 1.32bn, and in 2Q26 revenue was KRW 6.20bn with an operating loss of KRW 0.70bn, so operating losses continued each quarter in the first half of 2026.

Second-quarter 2026 revenue slipped from KRW 6.40bn a year earlier while the operating loss widened from KRW 0.29bn to KRW 0.70bn. Unless core revenue recovers above the KRW 30bn level, reaching breakeven remains structurally difficult.

Repeated timeline changes and regulatory uncertainty

The Phase 3 application originally set for February 2026 was pushed back until after the FDA meeting; plans then shifted to a June IND filing and a September accelerated-approval request, and were later reframed as a second-half pre-BLA meeting with a November BLA submission target.

Shareholder pushback was reported as the schedule slipped versus plan. The company describes the changes as strategic adjustments to raise the chance of approval, but any approval depends on FDA judgment and further trial design.

For a stock in which event expectations are embedded in the price, timeline changes are themselves a volatility factor.

Funding burden of large investment and listing plans

The company said it will invest USD 300m over five years in the BIOSTAR Stemcell Campus in Baltimore and targets one million doses a year by 2031. Yet 2025 operating cash flow of KRW 0.16bn was effectively breakeven, so internal cash cannot fund plans of that scale.

The Nasdaq ADR listing is a funding channel, but whether the listing actually completes is itself cited as a variable, and delay could increase the need to raise capital in the domestic market. Depending on the funding route, potential dilution for existing shareholders also has to be considered.

Risk factors

Regulatory and litigation

The MFDS appealed the first-instance ruling to the Seoul High Court on July 30, 2026, and NatureCell disclosed this on July 31, saying it had retained a law firm to respond.

Legal experts describe the ruling as connected to the foundations of Korea's drug review system, and the appellate outcome could materially shift any domestic commercialization timing. In the US as well, CMC, process consistency and long-term safety data can be reviewed comprehensively during BLA assessment. In both markets approval remains a process under way rather than a settled fact.

Earnings volatility

Quarterly revenue swung from KRW 3.90bn in 3Q25 to KRW 6.35bn in 4Q25, KRW 4.06bn in 1Q26 and KRW 6.20bn in 2Q26, a wide amplitude. In that structure a single quarter is a poor guide to trend, and shifts in cosmetics and beverage sales plus one-off items feed straight into the bottom line.

In 4Q25 the company reported net profit of KRW 0.34bn despite an operating loss of KRW 0.26bn, a case where non-operating items flipped the net result. Quarters in which operating and net results move in opposite directions may recur.

Embedded expectations and governance or shareholder issues

The company's market value reflects approval and listing scenarios far more than current earnings, so schedule slippage or a change in regulatory judgment can translate directly into volatility.

On the shareholder side, the representative said 1,786 shareholders holding 12.78% of the stock, or about 8.23 million shares, had backed shareholder-rights action through an activist platform, and opposition to March general meeting agenda items was also reported.

Continuing friction in company-shareholder communication could affect decision timelines. In addition, because the JointStem license applicant and the holder of domestic sales rights are separate entities, the contractual structure between affiliates affects how any eventual revenue is shared.

What to watch next

September-October 2026
Whether the second-half pre-BLA meeting with the FDA that the company flagged actually takes place, and what comes out of it. This step checks whether the filing package is sufficient, making it the first gauge of whether the November BLA target is achievable.
October 2026
Whether the GMP center in Baltimore, Maryland is completed. The company said completion would allow supply of 20,000 doses a year, so the completion date and initial operating status serve as a physical gauge of US commercialization readiness.
November 2026
The JointStem BLA submission target cited by the shareholder representative, and whether the Nasdaq level 3 ADR listing application is filed within the company's stated September-November 2026 window. Both are events verifiable through disclosures and company announcements.
During November 2026
The 3Q26 report filing. Key checks are whether revenue recovers and the operating loss narrows against 3Q25 revenue of KRW 3.90bn and an operating loss of KRW 1.39bn, and whether the US cosmetics sales the company said would start in September show up in revenue.
Fourth quarter 2026 onward
Progress of the appeal at the Seoul High Court. Since the MFDS appealed the first-instance ruling, the hearing schedule and framing of the issues will drive when a domestic license review can resume, and the company said it will re-disclose developments as they are confirmed.

Overall view

NatureCell is a stock with a very wide gap between confirmed earnings and the future the market anticipates.

It posted revenue of KRW 32.3bn and operating profit of KRW 0.6bn in 2024, then reverted to revenue of KRW 20.7bn and an operating loss of KRW 3.6bn in 2025, with operating losses continuing in both 1Q26 and 2Q26 so the four most recent quarters combined remain loss-making.

On the other side, JointStem holds RMAT and Breakthrough Therapy designations in the US and went through an FDA meeting on May 21, 2026; the company says it will pursue a filing after a second-half pre-BLA meeting, and it is also pushing a Nasdaq ADR listing and the Baltimore GMP center in parallel.

Domestically, after the July 9 first-instance win the MFDS appealed on July 30, moving the dispute to the appellate court, and observers note that winning the administrative suit does not equal a product license.

The balance sheet carries a light debt burden at an 18.6% debt-to-equity ratio, but with 2025 operating cash flow effectively at breakeven the large US investment plan cannot be funded internally.

What matters to verify, then, is execution against dates rather than narrative: the pre-BLA meeting and its outcome, the BLA submission, the listing application, GMP completion and the appeal's progress are all checkable in sequence. This report is for information purposes only and contains no buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.